Headaches, ovarian cysts, nausea and upper respiratory tract infections occurred in more than 10% of women in clinical trials. In men, the most serious adverse events reported were testicular surgery for cryptorchidism which existed prestudy, hemoptysis, an infected pilonidal cyst, and lymphadenopathy associated with an Epstein-Barr viral infection. Other concerns include overstimulation of the ovaries, pulmonary and vascular complications and multiple births. Post-marketing reports revealed hypersensitivity reactions including anaphylactoid reactions and asthma. Follitropin is contraindicated in pregnant women. No studies have been done in nursing mothers.
Follitropin is a human follicle stimulating hormone (FSH) preparation of recombinant DNA origin, which consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta- subunits. The alpha- and beta- subunits have 92 and 111 amino acids. The alpha subunit is glycosylated at Asn 51 and Asn 78 while the beta subunit is glycosylated at Asn 7 and Asn 24. Follitropin beta is produced in genetically engineered Chinese hamster cell lines (CHO). The nomenclature “beta” differentiates it from another recombinant human FSH product that was marketed earlier as follitropin alpha. Follitropin is important in the development of follicles produced by the ovaries. Given by subcutaneous injection, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. Follitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF). Numerous physio-chemical tests and bioassays indicate that follitropin beta and follitropin alpha are indistinguishable. However, a more recent study showed there is may be a slight clinical difference, with the alpha form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but with significantly higher estradiol (E2) levels. Structural analysis shows that the amino acid sequence of follitropin beta is identical to that of natural human follicle stimulating hormone (FSH). Further, the ogliosaccharide side chains are very similar, but not completely identical to that of natural FSH. However, these small differences do not affect the bioactivity compared to natural FSH.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Fluvoxamine | The therapeutic efficacy of Follitropin can be decreased when used in combination with Fluvoxamine. |
| Citalopram | The therapeutic efficacy of Follitropin can be decreased when used in combination with Citalopram. |
| Fluoxetine | The therapeutic efficacy of Follitropin can be decreased when used in combination with Fluoxetine. |
| Duloxetine | The therapeutic efficacy of Follitropin can be decreased when used in combination with Duloxetine. |
| Trazodone | The therapeutic efficacy of Follitropin can be decreased when used in combination with Trazodone. |
| Paroxetine | The therapeutic efficacy of Follitropin can be decreased when used in combination with Paroxetine. |
| Sertraline | The therapeutic efficacy of Follitropin can be decreased when used in combination with Sertraline. |
| Sibutramine | The therapeutic efficacy of Follitropin can be decreased when used in combination with Sibutramine. |
| Nefazodone | The therapeutic efficacy of Follitropin can be decreased when used in combination with Nefazodone. |
| Escitalopram | The therapeutic efficacy of Follitropin can be decreased when used in combination with Escitalopram. |
| Zimelidine | The therapeutic efficacy of Follitropin can be decreased when used in combination with Zimelidine. |
| Dapoxetine | The therapeutic efficacy of Follitropin can be decreased when used in combination with Dapoxetine. |
| Milnacipran | The therapeutic efficacy of Follitropin can be decreased when used in combination with Milnacipran. |
| Desvenlafaxine | The therapeutic efficacy of Follitropin can be decreased when used in combination with Desvenlafaxine. |
| Seproxetine | The therapeutic efficacy of Follitropin can be decreased when used in combination with Seproxetine. |
| Indalpine | The therapeutic efficacy of Follitropin can be decreased when used in combination with Indalpine. |
| Ritanserin | The therapeutic efficacy of Follitropin can be decreased when used in combination with Ritanserin. |
| Alaproclate | The therapeutic efficacy of Follitropin can be decreased when used in combination with Alaproclate. |
| Amphetamine | The risk or severity of adverse effects can be increased when Amphetamine is combined with Follitropin. |
| Phentermine | The risk or severity of adverse effects can be increased when Phentermine is combined with Follitropin. |
| Midodrine | The risk or severity of adverse effects can be increased when Midodrine is combined with Follitropin. |
| Norepinephrine | The risk or severity of adverse effects can be increased when Norepinephrine is combined with Follitropin. |
| Phenylephrine | The risk or severity of adverse effects can be increased when Phenylephrine is combined with Follitropin. |
| Phenylpropanolamine | The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Follitropin. |
| Metaraminol | The risk or severity of adverse effects can be increased when Metaraminol is combined with Follitropin. |
| Epinephrine | The risk or severity of adverse effects can be increased when Epinephrine is combined with Follitropin. |
| Methoxamine | The risk or severity of adverse effects can be increased when Methoxamine is combined with Follitropin. |
| Orciprenaline | The risk or severity of adverse effects can be increased when Orciprenaline is combined with Follitropin. |
| Phenmetrazine | The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Follitropin. |
| Dobutamine | The risk or severity of adverse effects can be increased when Dobutamine is combined with Follitropin. |
| Pseudoephedrine | The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Follitropin. |
| Benzphetamine | The risk or severity of adverse effects can be increased when Benzphetamine is combined with Follitropin. |
| Ritodrine | The risk or severity of adverse effects can be increased when Ritodrine is combined with Follitropin. |
| Terbutaline | The risk or severity of adverse effects can be increased when Terbutaline is combined with Follitropin. |
| Oxymetazoline | The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Follitropin. |
| Diethylpropion | The risk or severity of adverse effects can be increased when Diethylpropion is combined with Follitropin. |
| Dopamine | The risk or severity of adverse effects can be increased when Dopamine is combined with Follitropin. |
| Isoprenaline | The risk or severity of adverse effects can be increased when Isoprenaline is combined with Follitropin. |
| Lisdexamfetamine | The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Follitropin. |
| Fenoterol | The risk or severity of adverse effects can be increased when Fenoterol is combined with Follitropin. |
| Ephedrine | The risk or severity of adverse effects can be increased when Ephedrine is combined with Follitropin. |
| Mephentermine | The risk or severity of adverse effects can be increased when Mephentermine is combined with Follitropin. |
| Procaterol | The risk or severity of adverse effects can be increased when Procaterol is combined with Follitropin. |
| Clenbuterol | The risk or severity of adverse effects can be increased when Clenbuterol is combined with Follitropin. |
| MMDA | The risk or severity of adverse effects can be increased when MMDA is combined with Follitropin. |
| Midomafetamine | The risk or severity of adverse effects can be increased when Midomafetamine is combined with Follitropin. |
| 2,5-Dimethoxy-4-ethylamphetamine | The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Follitropin. |
| 4-Bromo-2,5-dimethoxyamphetamine | The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Follitropin. |
| Tenamfetamine | The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Follitropin. |
| Chlorphentermine | The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Follitropin. |
| Methylenedioxyethamphetamine | The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Follitropin. |
| Dextroamphetamine | The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Follitropin. |
| Metamfetamine | The risk or severity of adverse effects can be increased when Metamfetamine is combined with Follitropin. |
| Nylidrin | The risk or severity of adverse effects can be increased when Nylidrin is combined with Follitropin. |
| Tetryzoline | The risk or severity of adverse effects can be increased when Tetryzoline is combined with Follitropin. |
| Tyramine | The risk or severity of adverse effects can be increased when Tyramine is combined with Follitropin. |
| Isoxsuprine | The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Follitropin. |
| Etilefrine | The risk or severity of adverse effects can be increased when Etilefrine is combined with Follitropin. |
| Synephrine | The risk or severity of adverse effects can be increased when Synephrine is combined with Follitropin. |
| Iofetamine I-123 | The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Follitropin. |
| Racepinephrine | The risk or severity of adverse effects can be increased when Racepinephrine is combined with Follitropin. |
| Ritobegron | The risk or severity of adverse effects can be increased when Ritobegron is combined with Follitropin. |
| Tramazoline | The risk or severity of adverse effects can be increased when Tramazoline is combined with Follitropin. |
| Mephedrone | The risk or severity of adverse effects can be increased when Mephedrone is combined with Follitropin. |
| Fenozolone | The risk or severity of adverse effects can be increased when Fenozolone is combined with Follitropin. |
| Methoxyphenamine | The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Follitropin. |
| Tretoquinol | The risk or severity of adverse effects can be increased when Tretoquinol is combined with Follitropin. |
| Gepefrine | The risk or severity of adverse effects can be increased when Gepefrine is combined with Follitropin. |
| Prenalterol | The risk or severity of adverse effects can be increased when Prenalterol is combined with Follitropin. |
| Mefenorex | The risk or severity of adverse effects can be increased when Mefenorex is combined with Follitropin. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Follitropin. |
| Labetalol | The risk or severity of adverse effects can be increased when Labetalol is combined with Follitropin. |
| Acebutolol | The risk or severity of adverse effects can be increased when Acebutolol is combined with Follitropin. |
| Celiprolol | The risk or severity of adverse effects can be increased when Celiprolol is combined with Follitropin. |
| Bucindolol | The risk or severity of adverse effects can be increased when Bucindolol is combined with Follitropin. |
| Epanolol | The risk or severity of adverse effects can be increased when Epanolol is combined with Follitropin. |
| Gefitinib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Gefitinib. |
| Sorafenib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Sorafenib. |
| Erlotinib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Erlotinib. |
| Imatinib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Imatinib. |
| Dasatinib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Dasatinib. |
| Lapatinib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Lapatinib. |
| Sunitinib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Sunitinib. |
| Genistein | The therapeutic efficacy of Follitropin can be decreased when used in combination with Genistein. |
| 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone | The therapeutic efficacy of Follitropin can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone. |
| Geldanamycin | The therapeutic efficacy of Follitropin can be decreased when used in combination with Geldanamycin. |
| PD173955 | The therapeutic efficacy of Follitropin can be decreased when used in combination with PD173955. |
| Radicicol | The therapeutic efficacy of Follitropin can be decreased when used in combination with Radicicol. |
| Cediranib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Cediranib. |
| Nilotinib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Nilotinib. |
| Vatalanib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Vatalanib. |
| Vandetanib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Vandetanib. |
| Canertinib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Canertinib. |
| Tandutinib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Tandutinib. |
| Motesanib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Motesanib. |
| Dovitinib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Dovitinib. |
| Glesatinib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Glesatinib. |
| Lestaurtinib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Lestaurtinib. |
| Pazopanib | The therapeutic efficacy of Follitropin can be decreased when used in combination with Pazopanib. |
| Midostaurin | The therapeutic efficacy of Follitropin can be decreased when used in combination with Midostaurin. |